Clinical Outcomes and Predictors of All-Cause Mortality After Complex High-Risk and Indicated Revascularization Using Percutaneous Coronary Intervention.

The concept of complex and high-risk indicated procedures using percutaneous coronary intervention (CHIP-PCI) has recently been defined. However, few studies have investigated the prognosis of patients after CHIP-PCI. We enrolled 322 consecutive patients who underwent CHIP-PCI. CHIP-PCI was defined as a procedure satisfying at least one criterion each for both patient and procedure characteristics, as follows: patient characteristics [age ≥ 75 years old, low left ventricular ejection fraction (LVEF), diabetes mellitus, acute coronary syndrome, previous coronary artery bypass surgery, peripheral arterial disease, severe chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and severe valvular disease] and procedure characteristics [unprotected left main disease, degenerated saphenous or radial artery grafts, severely calcified lesions, last patent conduit, chronic total occlusions, multivessel disease, and use of mechanical circulatory support]. On Kaplan-Meier analysis, 1-, 2-, and 3-year survival rates following CHIP-PCI was 93.8%, 89.2%, and 85.4%, respectively. Moreover, on Cox multivariate hazard analysis, age (≥ 75 years old) (hazard ratio: 4.01, 95% confidence interval: 1.92-8.38, P < 0.01), COPD (hazard ratio: 2.95, 95% confidence interval: 1.38-6.32, P < 0.01), low LVEF (hazard ratio: 3.35, 95% confidence interval: 1.55-7.22, P < 0.01), severe CKD (hazard ratio: 3.02, 95% confidence interval: 1.44-6.36, P < 0.01), and use of mechanical circulatory support (hazard ratio: 5.97, 95% confidence interval: 2.72-13.10, P < 0.01) remained significant predictors of mortality. In conclusion, we revealed the clinical outcomes after CHIP-PCI. The presence of advanced age, COPD, low LVEF, severe CKD, and mechanical circulatory support use might lead to worse clinical outcomes.

[1]  J. Spratt,et al.  Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome? , 2020, American heart journal.

[2]  Armando Pérez de Prado,et al.  Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI: Italian Society of Interventional Cardiology Working Group Endorsed by Spanish and Portuguese Interventional Cardiology Societies. , 2019, International journal of cardiology.

[3]  C. Toma,et al.  Impact of Chronic Kidney Disease and Anemia on Outcomes After Percutaneous Coronary Revascularization. , 2019, The American journal of cardiology.

[4]  A. Colombo,et al.  Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention. , 2019, International journal of cardiology.

[5]  F. Neumann,et al.  'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization. , 2019, European heart journal.

[6]  Anna C. Porter,et al.  Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease , 2017, JAMA cardiology.

[7]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. , 2016, Journal of the American College of Cardiology.

[8]  K. Park,et al.  Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry. , 2016, JACC. Cardiovascular interventions.

[9]  R. Wilensky,et al.  Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). , 2014, The American journal of cardiology.

[10]  M. Budoff,et al.  Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  Antonio Colombo,et al.  Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. , 2011, European heart journal.

[12]  A. Jaffe,et al.  Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.